Proteus Digital Health Launches Digital Oncology Drugs

Proteus Digital Health, Inc., Fairview Health Services and the University of Minnesota Health recently unveiled the Digital Oncology Drug Management Model at the ASCO-GI 2019 Symposium on Gastrointestinal Cancers , in San Francisco.

The collaboration announced that, for the first time, cancer patients were using digital drugs in oncology to improve their treatment regimen and improve their outcomes. This breakthrough helps patients complete oral chemotherapy cycles, while oncologists gain new insights into the progress of their patients' treatment and overall health.

Proteus has developed the model of care for oral digital oncology drugs with the University of Minnesota Health and Fairview, which is the first health care system in the world to prescribe digital capecitabine, a common chemotherapy drug prescribed with the Proteus ingestible sensor. It is currently used to treat patients with colorectal cancer at stages 3 and 4.

Dr. Edward Greeno, a physician oncologist / hematologist at the University of Minnesota, said: "Proteus has given us an excellent opportunity to capture our pbadion for better care management of patients receiving oral oncolytics and to progress in this direction because we were starting to do things right now. Proteus Digital Oral Chemotherapy provides a much more direct connection to the patient. This allows us to accomplish many things when a patient is in the clinic for infusions without him coming in person. In addition, we can learn from the patient that a visit to the office does not teach, as does the patient with his treatment regimen at home, every day. "

The digital drug program helps optimize treatment regimens while preserving the patient's privacy. The program captures, records and securely shares information about the time, dose and type of oral chemotherapy medication taken. This information, as well as data on rest, activity and resting heart rate, can be shared with the patient's consent with their doctor, pharmacist or manager. The information can only be accessed by the patient and the designated persons with the aid of a secure and user-friendly mobile platform developed by Proteus.

Andrew Thompson, CEO and co-founder of Proteus Digital Health, said: "Currently, providers are making decisions about oral chemotherapy based on the best patient knowledge of medication. For the first time, digital oncology drugs provide providers and providers with new information and the ability to communicate more specific information about the remote care of patients with colorectal cancer. Based on our data on the use of digital medicines in other treatment areas, we believe this will allow cancer patients to stay on treatment longer, avoid hospitalizations and respond better to treatment. in general. "

Paul Morales, Fairview Infusion Pharmacy Manager at the Center for Surgery and Surgery at the University of Minnesota, said, "Given the costs, complexity and risk of toxicity of oral chemotherapy, digital medicine in oncology is an exciting step forward in the treatment of cancer. For pharmacists, this helps us identify patients who may be struggling to take their medications properly and to intervene, for example by calling them to explain how to progress safely if they miss a dose. For patients, this helps them feel in control as they play a more active role in managing their medications. The results are better for patients. "

In order to gather more experiences and concrete data from cancer patients using digital medicines, Proteus is launching a digital registry of oral oncolytic drugs. This study will collect data from multiple sites, covering academic medical centers, community practices, and urban or rural facilities. Patients at participating sites will receive digital capecitabine to help with their treatment. The data collected as part of the study will be used to share best practices across multiple sites, enabling richer badysis of data and results.